Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.89 USD | -3.30% | -15.86% | -40.52% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-40.52% | 775M | C+ | ||
+2.49% | 96.73B | B+ | ||
-0.23% | 21.31B | B | ||
-16.61% | 21.21B | B+ | ||
-5.01% | 18.79B | A- | ||
-42.14% | 16.37B | A- | ||
-27.40% | 13.68B | B | ||
+1.44% | 13.44B | C+ | ||
+21.29% | 10.98B | C+ | ||
-21.79% | 8.56B | D |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- SAGE Stock
- Ratings Sage Therapeutics, Inc.